Cellectis is a clinical-stage biopharmaceutical company that develops immunotherapies for cancer and other diseases. The company's proprietary gene editing technology, TALEN, allows for the precise modification of genes in living cells, which can be used to create new therapies for a variety of diseases. Cellectis was founded in 1999 and is headquartered in Paris, France.